Advertisement
IQV vs IRIX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IQV is a StrongBuy and IRIX is a Hold.
IQV in +3.91% Uptrend, growing for three consecutive days on October 22, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where IQV advanced for three days, in 187 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on IQV as a result. In 46 of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.
The Moving Average Convergence Divergence (MACD) for IQV just turned positive on October 21, 2026. Looking at past instances where IQV's MACD turned positive, the stock continued to rise in 26 of 42 cases over the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 113 of 222 cases where IQV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IQV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
IQV broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 5 (best 1 - 100 worst), indicating outstanding price growth. IQV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 43 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.379) is normal, around the industry mean (66.046). P/E Ratio (34.068) is within average values for comparable stocks, (2.422). Projected Growth (PEG Ratio) (0.985) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.693) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 90 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IQV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
IRIX sees MACD Histogram just turned negative
IRIX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 21, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 39 instances where the indicator turned negative. In 35 of the 39 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for IRIX moved out of overbought territory on October 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 22 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IRIX as a result. In 85 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
IRIX broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
IRIX moved above its 50-day moving average on October 07, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IRIX crossed bullishly above the 50-day moving average on October 12, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 57%.
Following a +32.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where IRIX advanced for three days, in 153 of 205 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 81 of 112 cases where IRIX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 72%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. IRIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-5.671) is normal, around the industry mean (2.874). P/E Ratio (-3.812) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (3.870) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.204) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IRIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
IQV | IRIX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 25 | 97 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 72 Overvalued | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 90 | 100 | |
SMR RATING 1..100 | 43 | 100 | |
PRICE GROWTH RATING 1..100 | 5 | 59 | |
P/E GROWTH RATING 1..100 | 31 | 23 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IQV's Valuation (72) in the Servicestothe Health Industry industry is in the same range as IRIX (78) in the Medical Specialties industry. This means that IQV’s stock grew similarly to IRIX’s over the last 12 months.
IQV's Profit vs Risk Rating (90) in the Servicestothe Health Industry industry is in the same range as IRIX (100) in the Medical Specialties industry. This means that IQV’s stock grew similarly to IRIX’s over the last 12 months.
IQV's SMR Rating (43) in the Servicestothe Health Industry industry is somewhat better than the same rating for IRIX (100) in the Medical Specialties industry. This means that IQV’s stock grew somewhat faster than IRIX’s over the last 12 months.
IQV's Price Growth Rating (5) in the Servicestothe Health Industry industry is somewhat better than the same rating for IRIX (59) in the Medical Specialties industry. This means that IQV’s stock grew somewhat faster than IRIX’s over the last 12 months.
IRIX's P/E Growth Rating (23) in the Medical Specialties industry is in the same range as IQV (31) in the Servicestothe Health Industry industry. This means that IRIX’s stock grew similarly to IQV’s over the last 12 months.
| IQV | IRIX | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 85% |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 67% |
| Momentum ODDS (%) | 1 day ago 61% | 1 day ago 86% |
| MACD ODDS (%) | 1 day ago 62% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 63% | 1 day ago 85% |
| TrendMonth ODDS (%) | 1 day ago 68% | 1 day ago 70% |
| Advances ODDS (%) | 1 day ago 62% | 15 days ago 75% |
| Declines ODDS (%) | 4 days ago 64% | 3 days ago 82% |
| BollingerBands ODDS (%) | 1 day ago 68% | 1 day ago 83% |
| Aroon ODDS (%) | 1 day ago 51% | 1 day ago 72% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IQV’s FA Score shows that 2 FA rating(s) are green while IRIX’s FA Score has 1 green FA rating(s).
- IQV’s FA Score: 2 green, 3 red.
- IRIX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IQV’s TA Score shows that 4 TA indicator(s) are bullish while IRIX’s TA Score has 5 bullish TA indicator(s).
- IQV’s TA Score: 4 bullish, 3 bearish.
- IRIX’s TA Score: 5 bullish, 5 bearish.
Price Growth
IQV (@Medical Specialties) experienced а +5.58% price change this week, while IRIX (@Medical/Nursing Services) price change was -6.84% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.15%. For the same industry, the average monthly price growth was -6.50%, and the average quarterly price growth was +42.74%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was -10.29%.
Reported Earning Dates
IQV is expected to report earnings on Oct 27, 2026.
IRIX is expected to report earnings on Nov 10, 2026.
Industries' Descriptions
@Medical Specialties (-3.15% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (-1.62% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
IQV and
Correlation & Price change
A.I.dvisor indicates that over the last year, IQV has been closely correlated with CRL. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if IQV jumps, then CRL could also see price increases.
| Ticker / NAME | Correlation To IQV | 1D Price Change % | ||
|---|---|---|---|---|
| IQV | 100% | +0.61% | ||
| CRL - IQV | 71% Closely correlated | -1.51% | ||
| TMO - IQV | 68% Closely correlated | -2.52% | ||
| RVTY - IQV | 59% Loosely correlated | +0.48% | ||
| A - IQV | 58% Loosely correlated | -2.17% | ||
| ICLR - IQV | 54% Loosely correlated | +0.10% | ||
More | ||||
IRIX and
Correlation & Price change
A.I.dvisor tells us that IRIX and NTRA have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IRIX and NTRA's prices will move in lockstep.
| Ticker / NAME | Correlation To IRIX | 1D Price Change % | ||
|---|---|---|---|---|
| IRIX | 100% | -0.70% | ||
| NTRA - IRIX | 30% Poorly correlated | -2.91% | ||
| NEO - IRIX | 27% Poorly correlated | -3.81% | ||
| IQV - IRIX | 27% Poorly correlated | +0.61% | ||
| MDXH - IRIX | 26% Poorly correlated | -14.34% | ||
| DRIO - IRIX | 26% Poorly correlated | -5.98% | ||
More | ||||